Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-115A vs AD-1151 PK and Safety Study
NCT07385235Phase 1Recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of revaprazan in gastric ulcer (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum concentration of drug in plasma at 24 hours and Area under the plasma concentration-time curve during dosing interval at 24 hours. Started Jan 2026; status: recruiting.
02
Drugs
revaprazan
03
Conditions
gastric ulcer
Beyond the preview
Go deeper on NCT07385235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07385235.